2017 | 2016 | 2015 | 2014
DateTitle 
December 10, 2017Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® (ruxolitinib) in Patients with Polycythemia Vera
- Long-term data reinforce Jakafi® (ruxolitinib) as an effective long-term treatment option for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea - Overall safety profile of Jakafi remained consistent with previously-reported 80-week RESPONSE data WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 10, 2017-- Incyte Corporation (Nasdaq:INCY) today announced new 208-week (4-year) fol... 
Printer Friendly Version
November 15, 2017Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 15, 2017-- Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the RESET pivotal trial evaluating ruxolitinib (Jakafi®) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant of hydroxyurea (HU). “We are pleased to treat the first patient in our pivotal trial evaluating ruxolitinib as a treatm... 
Printer Friendly Version
November 05, 2017ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo
- Post-hoc analysis presented at ACR/ARHP shows pain improvement was consistent regardless of a patient's baseline pain severity INDIANAPOLIS, Nov. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that patients with moderate-to-severe rheumatoid arthritis (RA) treated with baricitinib reported greater improvements in pain control when compared to Humira®* (adalimumab) or placebo. A new post-hoc analysis of the Phase 3 RA-BEAM s... 
Printer Friendly Version
November 01, 2017More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59th Annual ASH Meeting
RESPONSE 4-year follow-up data for Jakafi® (ruxolitinib) in patients with polycythemia vera accepted as oral presentation WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 1, 2017-- Incyte Corporation (Nasdaq:INCY) announces that more than 30 abstracts including data from its clinical development programs for Jakafi® (ruxolitinib), JAK1, PI3Kδ, PIM and BRD will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting 2017... 
Printer Friendly Version
October 31, 2017Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs
$304 million of 2017 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 36 percent growth over the same period last year Progress across the portfolio as multiple candidates enter late-stage development trials Two recent collaborations further expand potential and scope of Incyte’s combination immunotherapy development activities Conference Call and Webcast Schedu... 
Printer Friendly Version
October 31, 2017Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer
Phase 3 trial evaluating Imfinzi and epacadostat in patients with locally-advanced, unresectable non-small cell lung cancer is expected to begin in first-half 2018 WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 31, 2017-- Incyte Corporation (Nasdaq:INCY) and MedImmune, AstraZeneca’s (NYSE:AZN) global biologics research and development arm, today announced the expansion of their clinical collaboration. As part of the agreement, the companies will eval... 
Printer Friendly Version
October 30, 2017Incyte Names New Member to Its Board of Directors
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 30, 2017-- Incyte Corporation (Nasdaq:INCY) today announced the appointment of Jacqualyn “Jackie” A. Fouse, Ph.D., as a new member of the Board of Directors, effective November 14, 2017. “We are pleased to welcome Jackie to Incyte. Her impressive background will further strengthen and add to the experience of our Board and leadership team,” stated Hervé Hoppenot, Incyte’s Chairman and Chief Executive... 
Printer Friendly Version
October 25, 2017Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012
Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications MacroGenics to receive an upfront cash payment of $150 million plus potential milestone payments and royalties, and retains right to develop its pipeline assets in combination with MGA012 WILMINGTON, Del. & ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 25, 2017-- Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NA... 
Printer Friendly Version
October 24, 2017Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 24, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 26th Annual Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 9:45am (MST) in Scottsdale, Arizona. The presentation will be webcast live and can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days. Investors interested in listening to ... 
Printer Friendly Version
October 12, 2017Incyte to Report Third Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 12, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 10:00 a.m. ET on Tuesday, October 31, 2017. The schedule for the press release and conference call/webcast is as follows:   • Q3 ... 
Printer Friendly Version
October 06, 2017Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware
Fund to provide emergency financial support for Delaware cancer patients and their families WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 6, 2017-- Incyte Corporation (Nasdaq:INCY) and Cancer Support Community Delaware (CSCDE) today announced the establishment of the Incyte Cancer Care Assistance Fund for Delaware which will provide emergency financial assistance for cancer patients, their caregivers and family members living in Delaware. T... 
Printer Friendly Version
September 14, 2017Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
- Results presented at EADV show baricitinib significantly improved clinical and patient-reported outcomes compared to placebo in moderate-to-severe atopic dermatitis patients - Improvements seen as early as first week of treatment in baricitinib-treated group - Lilly will initiate a Phase 3 clinical program for moderate-to-severe atopic dermatitis later this year INDIANAPOLIS, Sept. 14, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today... 
Printer Friendly Version
September 09, 2017Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
Updated Data to be Presented at ESMO 2017 Congress WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 9, 2017-- Incyte Corporation (Nasdaq:INCY) today announced updated data from the ongoing Phase 1/2 ECHO-202 trial (KEYNOTE-037) evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, NJ USA (known as MSD outside the United States and ... 
Printer Friendly Version
September 09, 2017Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
Updated Data to be Presented at ESMO 2017 Congress WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Sep. 9, 2017-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the ongoing Phase 1/2 ECHO-202 trial (KEYNOTE-037) evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ... 
Printer Friendly Version
September 08, 2017Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2017-- Incyte Corporation (Nasdaq: INCY) (the “Company”) today announced the pricing of its underwritten public offering of 4,945,000 shares of its common stock. The Company has granted the underwriter an option to purchase up to an additional 741,750 shares of common stock. The offering is expected to close on September 12, 2017, subject to customary closing conditions. The Company intends to use... 
Printer Friendly Version
September 07, 2017Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 7, 2017-- Incyte Corporation (Nasdaq: INCY) (the “Company”) today announced that the Company intends to offer to sell, subject to market and other conditions, 4,945,000 shares of its common stock in an underwritten public offering. In connection with the offering, the Company expects to grant the underwriter an option to purchase up to an additional 741,750 shares on the same terms and conditions. Th... 
Printer Friendly Version
September 01, 2017Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month
New resources are now available to help patients track their disease and activate the community to increase awareness of rare blood cancers Facebook Live Q&A to be held on MPN Awareness Day, September 14, 2017, from 7:00-8:00 p.m. ET WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 1, 2017-- Incyte Corporation (NASDAQ:INCY) is proud to recognize and support the patients of the MPN community throughout September in ho... 
Printer Friendly Version
August 30, 2017New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
Updated Phase 1 and new Phase 2 data from the ECHO-202 trial to be highlighted as an oral presentation at ESMO 2017 Congress WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 30, 2017-- Incyte Corporation (Nasdaq:INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1214O) containing new and updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, ... 
Printer Friendly Version
August 30, 2017Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018
INDIANAPOLIS , Aug. 30, 2017 /PRNewswire/ -- Eli Lilly and Company ( NYSE : LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug Administration (FDA) in late August, Lilly will resubmit the New Drug Application (NDA) for baricitinib before the end of January 2018 . The resubmission package will include new safety and efficacy data. The companies anticipate the FDA will classify the application ... 
Printer Friendly Version
August 10, 2017Forbes Magazine Names Incyte One of the World’s Most Innovative Companies for Third Consecutive Year
Company ranked 6th in 2017 and in Top 10 for Third Year Running WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 10, 2017-- Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 6th on Forbes magazine’s 2017 list of the World’s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small m... 
Printer Friendly Version
August 01, 2017Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs
$276 million of 2017 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 33 percent growth over the same period last year Proof-of-concept data for the combination of epacadostat plus PD-1 inhibition presented at the American Society of Clinical Oncology Annual Meeting (ASCO) 2017 across multiple tumor types; expanded Phase 3 program on track for planned initiation in 2017 Mult... 
Printer Friendly Version
July 25, 2017Lilly and Incyte Provide Update on Baricitinib
INDIANAPOLIS , July 25, 2017 /PRNewswire/ -- Eli Lilly and Company ( NYSE : LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA), will be delayed beyond 2017. The companies will be further discussing the path forward with the agency and evaluating options for resubmiss... 
Printer Friendly Version
July 20, 2017Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 20, 2017-- Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-301, a pivotal Phase 3 trial for the first-line treatment of patients with acute graft-versus-host disease (GVHD). The trial will evaluate the efficacy and safety of itacitinib, Incyte’s novel, potent, and selective JAK1 inhibitor, in combination with corticosteroids compared to placebo plus corticosteroi... 
Printer Friendly Version
July 11, 2017Incyte to Report Second Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 11, 2017-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 10:00 a.m. ET on Tuesday, August 1, 2017. The schedule for the press release and conference call/webcast is as follows:       ... 
Printer Friendly Version
July 03, 2017Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis
INDIANAPOLIS, July 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant® (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies. The Olumiant approval is based on the results of the barici... 
Printer Friendly Version
June 16, 2017New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serious infection incidents. Additionally, new data from the long-term extension (LTE) of Phase 3 trials showed that two years of baricitinib treatment sig... 
Printer Friendly Version
June 13, 2017Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)
INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the Olumiant® (baricitinib) clinical trials will be presented in 21 abstracts, including one oral presentation, at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, June 14-17, 2017. Lilly will also present six abstracts evaluating Taltz® (ixekizumab) for the treatment of psoriatic arthri... 
Printer Friendly Version
June 07, 2017Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 7, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017 at 10:40 am (PDT) / 1:40 pm (EDT) in Rancho Palos Verdes; William Blair 2017 Growth Stock Conference on Wednesday, June 14, 2017 at 10:00 am (... 
Printer Friendly Version
June 05, 2017Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 5, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that data from ongoing investigational studies of epacadostat in combination with pembrolizumab (ECHO-202) and nivolumab (ECHO-204) in multiple tumor types will be discussed at an Analyst and Investor Event this evening, Monday, June 5, 2017. These data are from posters and presentations at the American Society for Clinical Oncology (ASCO) Annual Meeting be... 
Printer Friendly Version
June 05, 2017Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer
These data supported advancing the clinical development program for epacadostat and Opdivo in these types of cancer Combination of IDO1 enzyme inhibition plus Opdivo was generally well-tolerated in patients with select advanced solid tumors WILMINGTON, Del. & and NEW YORK--(BUSINESS WIRE)--Jun. 5, 2017-- Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced updated data from the ongoing Phase 1/2 ... 
Printer Friendly Version
June 05, 2017Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types
Responses observed with combination of IDO1 enzyme inhibition and anti-PD-1 therapy support advancing into broad Phase 3 program Safety data for this novel investigational immunotherapy combination are generally similar to KEYTRUDA monotherapy WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jun. 5, 2017-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that up... 
Printer Friendly Version
June 03, 2017Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Updated Phase 1/2 data from ECHO-202 investigating the combination of IDO1 enzyme inhibition and anti-PD-1 therapy in patients with advanced NSCLC, regardless of PD-L1 status, presented at 2017 ASCO Annual Meeting WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 3, 2017-- Incyte Corporation (NASDAQ:INCY) today announced updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing Phase 1/2 ECHO-202 trial, evaluating epacados... 
Printer Friendly Version
June 03, 2017Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Updated Phase 1/2 data from ECHO-202 investigating the combination of IDO1 enzyme inhibition and anti-PD-1 therapy in patients with advanced NSCLC, regardless of PD-L1 status, presented at 2017 ASCO Annual Meeting WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jun. 3, 2017-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell... 
Printer Friendly Version
May 22, 2017Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May 22, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 2017 Growth Stock Conference on Wednesday, June 14, 2017 at 10:00 am (CDT) in Chicago; and Nasdaq 36th Investor Program on Thursday, June 15, 2017 at 11:00 am (BST) in London The presentations will... 
Printer Friendly Version
May 17, 2017New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® (pembrolizumab)
Incyte’s IDO1 enzyme inhibitor in combination with Merck’s anti-PD-1 therapy is well-tolerated and demonstrates durable clinical responses across multiple solid tumors WILMINGTON, Del.--(BUSINESS WIRE)--May 17, 2017-- Incyte Corporation (Nasdaq:INCY) today announced the publication of new data from the ongoing ECHO-202 trial, evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Keytruda® (pembrolizumab), Merck’... 
Printer Friendly Version
May 17, 2017First Data from Combination of Epacadostat with Opdivo® (nivolumab) Will Be Highlighted at ASCO 2017
Combination is well-tolerated and demonstrates promising clinical outcomes in multiple advanced solid tumors WILMINGTON, Del.--(BUSINESS WIRE)--May 17, 2017-- Incyte Corporation (Nasdaq:INCY) today announced that the American Society of Clinical Oncology (ASCO) has published Phase 1/2 data from the ongoing ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Opdivo® (ni... 
Printer Friendly Version
May 04, 2017Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
$251 million of 2017 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 37 percent growth over the same period last year Expanded ECHO program for epacadostat to include multiple pivotal trials in patients with melanoma, non-small cell lung, head & neck, bladder, and renal cancers in combination with PD-1 inhibitors Olumiant® (baricitinib) approved by the European Commissio... 
Printer Friendly Version
April 25, 2017Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 25, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 10:00 am (PDT) in Las Vegas; and UBS Global Healthcare Conference on Monday, May 22, 2017 at 11:30 am (EDT) in New York The... 
Printer Friendly Version
April 20, 2017Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting
Presentations to include data from the ECHO-202 trial of epacadostat plus KEYTRUDA® (pembrolizumab) and initial data from the ECHO-204 trial of epacadostat plus Opdivo® (nivolumab) WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 20, 2017-- Incyte Corporation (Nasdaq: INCY) announces that more than 15 abstracts highlighting its research and development portfolio in immuno-oncology and targeted therapies will be presented at the upcoming 2017 American ... 
Printer Friendly Version
April 18, 2017Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 18, 2017-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 10:00 a.m. ET on Thursday, May 4, 2017. The schedule for the press release and conference call/webcast is as follows: • Q1 2017 Press Release:   ... 
Printer Friendly Version
April 14, 2017U.S. FDA Issues Complete Response Letter for Baricitinib
INDIANAPOLIS--(BUSINESS WIRE)--Apr. 14, 2017-- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA). This Smart News Release features multimedia. View the full r... 
Printer Friendly Version
April 02, 2017Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials
Companies to initiate Phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017 Collaboration will add additional I-O relapsed/refractory melanoma cohorts to ECHO-204, the ongoing Phase 1/2 multi-tumor study of epacadostat plus Opdivo NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Incyte Corporation (Na... 
Printer Friendly Version
March 31, 2017Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)
Clinical Program Now Includes Seven Registrational Trials Across Five Tumor Types WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Mar. 31, 2017-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, wit... 
Printer Friendly Version
March 02, 2017Incyte’s Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abstracts at the AACR Annual Meeting 2017
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 2, 2017-- Incyte Corporation (Nasdaq:INCY) announces that 20 abstracts from its research and development portfolio will be presented at the upcoming 2017 American Association for Cancer Research (AACR) annual meeting in Washington, D.C. from April 1-5, 2017. These abstracts include a clinical data presentation from the dose-escalation phase of the Company’s ongoing trial of its selective FGFR 1/2/3 inhibitor ... 
Printer Friendly Version
February 28, 2017Incyte Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disease Day 2017
February 28, 2017, commemorates the tenth annual Rare Disease Day Incyte supports efforts to raise awareness and improve diagnosis and treatment for the nearly 200,000 people in the United States with MPNs, a group of rare blood cancers WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 28, 2017-- Incyte Corporation (Nasdaq:INCY) joins the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURODI... 
Printer Friendly Version
February 23, 2017Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania
Collaboration aims to advance the understanding of cancer biology and foster innovative science in immunotherapy WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 23, 2017-- Incyte Corporation (Nasdaq:INCY) today announces a multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania. Through this collaboration, Incyte and Abramson have agreed to bring together the knowledge and expertise of their leading drug dis... 
Printer Friendly Version
February 21, 2017Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 21, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:00 am (EST) in Boston; and Barclays Capital Global Healthcare Conference on Wednesday, March 15, 2017 at 2:35 pm (EDT) in Miami ... 
Printer Friendly Version
February 15, 2017Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo
INDIANAPOLIS ,Feb. 15, 2017/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) – were published in the New England Journal of Medicine.The New England Journal of Medicine publication includes supplementary data, which show that starting as early as week 8, and sustained through week 52, a h... 
Printer Friendly Version
February 14, 2017Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
$238 million of 2016 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 30 percent growth over the same period last year and $853 million of 2016 full-year net product revenues from Jakafi, representing 42 percent growth over last year Multiple pivotal programs expected to commence this year, including the combination of epacadostat and pembrolizumab in four additional solid tumor indications ... 
Printer Friendly Version
February 14, 2017Incyte and Agenus Amend Collaboration Agreement
Incyte secures global clinical development and commercialization responsibilities for GITR and OX40 programs, converting both from profit-sharing to royalty-bearing arrangements Agenus to receive $80 million from Incyte: $60 million equity investment at $6 per share and $20 million in accelerated clinical development milestones WILMINGTON, Del. & LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 14, 2017-- Incyte Corporation (Nasdaq:INCY) an... 
Printer Friendly Version
February 13, 2017European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU INDIANAPOLIS, Feb. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or w... 
Printer Friendly Version
January 30, 2017Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
Incyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158 Calithera conference call scheduled... 
Printer Friendly Version
January 24, 2017Incyte to Report Fourth Quarter and Year-End Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 24, 2017-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter and year end 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, February 14, 2017. The schedule for the press release and conference call/webcast is as follows:      ... 
Printer Friendly Version
January 13, 2017U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA). The NDA for baricitinib was submitted to the FDA in January 2016.The FDA extended the action date to allow time to review ... 
Printer Friendly Version
January 09, 2017Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)
Additional pivotal studies evaluating Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jan. 9, 2017-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical de... 
Printer Friendly Version
RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet